Financials in USD. Standardized financial statements.
A compact view of how ARS Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $84.28M | $89.15M | $30,000 | $1.32M | $5.51M | $17.84M | $0 | $0 |
| Revenue Growth? | -5.5% | +297063.3% | -97.7% | -76.1% | -69.1% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $20.42M | $20.56M | $0 | $17.12M | $213,000 | $14.07M | $1.55M | $1.42M |
| Gross Profit? | $63.85M | $68.59M | $30,000 | -$15.80M | $5.29M | $3.77M | -$1.55M | -$1.42M |
| Gross Margin? | +75.8% | +76.9% | +100.0% | -1200.9% | +96.1% | +21.1% | 0.0% | 0.0% |
| Operating Expenses? | $243.30M | $71.67M | $67.55M | $19.71M | $24.75M | $4.23M | $22.52M | $16.90M |
| Operating Income? | -$179.45M | -$3.08M | -$67.52M | -$35.52M | -$19.45M | -$469,000 | -$24.07M | -$18.32M |
| EBITDA? | -$178.08M | -$3.00M | -$67.45M | -$35.20M | -$19.24M | -$463,000 | -$22.52M | -$16.90M |
| Income Before Tax | -$171.38M | $8.29M | -$54.37M | -$34.68M | -$20.24M | -$1.06M | -$23.97M | -$17.58M |
| Income Tax Expense | -$80,000 | $288,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$171.30M | $8.00M | -$54.37M | -$34.68M | -$20.24M | -$1.06M | -$23.97M | -$17.58M |
| EPS? | $-1.74 | $0.08 | $-0.57 | $-0.87 | $-0.70 | $-0.03 | $-0.72 | $-0.53 |
| Diluted EPS? | $-1.74 | $0.08 | $-0.57 | $-0.87 | $-0.70 | $-0.03 | $-0.72 | $-0.53 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality